Abbott snags $1B U.S. government contract for rapid COVID-19 tests Optum acquires Refresh Mental Health: report Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod Icosavax's COVID-19 shot fails to deliver in early data, spurring debate about 'fatal flaw' in platform Moderna weighs private market debut for COVID shot as federal funding flounders Roche, Bristol Myers partner to develop digital pathology AI to analyze clinical trial assays Amid warnings of potential Russian cyberattacks, new Senate bill directs CISA, HHS to shore up digital defenses AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer Medtronic kicks off pivotal study of tibial neuromodulation implant for overactive bladder Jazz grows cannabinoid manufacturing ambitions with new $100M plant 89bio gains a little more confidence in NASH treatment with new hormone data AHA invests in venture capital firm SteelSky, which funds women's health startups Sight Sciences plots move into drug-device combos after seeing revenue surge 77% #FierceMadness: Boudreaux, Brooks-LaSure narrowly advance to Sweet 16 Featured Story | By Conor Hale The award is one of several steps toward the Biden administration’s redoubled goal of delivering 1 billion free tests to U.S. homes following the rise of the omicron variant. read more |
| |
|---|
|
Top Stories By Paige Minemyer Optum has quietly acquired Refresh Mental Health from private equity firm Kelso & Company, Axios reported Thursday. read more By Fraiser Kansteiner The FDA has pushed back its decision on Reblozyl, also known as luspatercept-aamt, by three months. The regulator now plans to issue a verdict on the drug for anemia in adults with non-transfusion dependent beta thalassemia by June 27. read more By Max Bayer Early underwhelming data from Icosavax's COVID-19 vaccine has sent investors sprinting towards the exits, bringing into question whether the biotech's entire platform has a "fatal flaw." read more By Fraiser Kansteiner As Congress gridlocks over new funding for COVID-19 therapies and vaccines, mRNA bigwig Moderna is setting its sights on the endemic market for its wildly successful shot. read more By Andrea Park It’s only been a few months since Roche started inviting artificial intelligence developers like PathAI into its cancer-focused digital pathology platform, but it’s already going all-in on the technological team-up. read more By Dave Muoio The legislation was brought to the Senate just days after the Biden administration warned of potential cyberattacks from Russia. read more By Nick Paul Taylor AN2 Therapeutics has found public investors willing to bet on biotech, enabling it to upsize its IPO and reel in $69 million for a pivotal trial of an antibiotic it picked up from Pfizer’s Anacor Pharmaceuticals. read more By Conor Hale After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. Now, it's testing a similar device implanted near the ankle instead. read more By Fraiser Kansteiner Jazz will invest more than $100 million into a new, 60,000-square-foot production facility in the U.K., where it also plans to hire 100 new staffers. The plant is expected to open in 2024, and it will specifically support manufacture of Jazz and GW’s two approved cannabis-based medicines. read more By Annalee Armstrong 89bio has gained a little more confidence in its non-alcoholic steatohepatitis therapy after new data showed the treatment increased levels of a key hormone linked to anti-inflammatory and anti-fibrotic activity in the liver. read more By Robert King The American Hospital Association made its latest foray into venture capital, becoming the newest investor in the women's health startup fund SteelSky Ventures. read more By Andrea Park Buoyed by tens of millions in new revenue and a successful IPO that brought in proceeds of more than a quarter-billion dollars, Sight Sciences is scoping out new avenues to deliver ophthalmic treatments. read more By Paige Minemyer This year, Fierce Healthcare's #FierceMadness is back, and we want you to help us identify the industry's most influential person. read more |
